Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Desmond Adamu

Urology McAllen, TX Medical Doctor

NPI 1477996585 CMS profile 2784539

1200 E Savannah Ave Ste 18, McAllen, TX 78503

Open in the dashboard

General payments

$4,341

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Desmond Adamu of McAllen, TX is reported in the CMS Open Payments database as having received $4,341 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $651 15
2024 General $356 17
2023 General $2,004 55
2022 General $153 8
2021 General $294 11
2020 General $285 10
2019 General $599 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Desmond Adamu
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Desmond Adamu were reported at $651. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Desmond Adamu Urology median Middle half National median
2019 $599 $480 $147–$1,201 $163
2020 $285 $246 $87–$645 $114
2021 $294 $358 $111–$1,000 $132
2022 $153 $476 $143–$1,263 $149
2023 $2,004 $560 $168–$1,461 $160
2024 $356 $563 $170–$1,464 $164
2025 $651 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,391 33 payments
  2. Boston Scientific Corporation $649 27 payments
  3. Astellas Pharma US Inc $422 20 payments
  4. PROCEPT BioRobotics Corporation $346 2 payments
  5. Pfizer Inc. $285 3 payments
  6. Janssen Biotech, Inc. $271 10 payments
  7. Coloplast Corp $239 5 payments
  8. Sumitomo Pharma America, Inc. $153 6 payments
  9. KCI USA, Inc $125 1 payment
  10. Myriad Genetic Laboratories, Inc. $118 6 payments
  11. Other $340 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,649 111 payments
  2. Travel and Lodging $1,255 10 payments
  3. Education $437 8 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM $1,391 33 payments
  2. XTANDI $563 22 payments
  3. AQUABEAM ROBOTIC SYSTEM $346 2 payments
  4. ERLEADA $271 10 payments
  5. ALTIS $172 3 payments
  6. AMS 700 $136 3 payments
  7. GEMTESA $128 5 payments
  8. VAC VERAFLO $125 1 payment
  9. PREVENA $125 1 payment
  10. rezum Generator $120 11 payments
  11. Other $960 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,703

Median for Urology: 1,053

Drug cost

$1,384,163

Median for Urology: $101,464

Branded share of claims

39.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 46 $699,478
Xtandi Enzalutamide Brand 36 $531,160
Gemtesa Vibegron Brand 91 $73,671
Myrbetriq Mirabegron Brand 63 $46,210
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 93 $6,534
Tamsulosin Hcl Generic 318 $4,763
Finasteride Generic 342 $4,622
Estradiol Generic 65 $4,347
Solifenacin Succinate Generic 58 $2,865
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 47 $2,541

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$105,683

Medicare's payments for the services billed

Medicare patients

257

Average age 75

Services billed

1,371

87 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 60%
Chronic kidney disease 53%
Arthritis 49%
Ischemic heart disease 48%
Heart failure 35%
Depression 32%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma Global Development $24
  • Astellas Pharma US Inc $14
$39 36 —
ERLEADA
  • Janssen Biotech, Inc. $34
$34 46 —
ORGOVYX
  • Sumitomo Pharma America, Inc. $25
$25 — —
AKEEGA
  • Janssen Biotech, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record